Rogiers, A., Pires da Silva, I., Tentori, C., Tondini, C. A., Grimes, J. M., Trager, M. H., Nahm, S., Zubiri, L., Manos, M., Bowling, P., Elkrief, A., Papneja, N., Vitale, M. G., Rose, A. A. N., Borgers, J. S. W., Roy, S., Mangana, J., Pimentel Muniz, T., Cooksley, T., Lupu, J., Vaisman, A., Saibil, S. D., Butler, M. O., Menzies, A. M., Carlino, M. S., Erdmann, M., Berking, C., Zimmer, L., Schadendorf, D., Pala, L., Queirolo, P., Posch, C., Hauschild, A., Dummer, R., Haanen, J., Blank, C. U., Robert, C., Sullivan, R. J., Ascierto, P. A., Miller Jr, W. H., Stephen Hodi, F., Suijkerbuijk, K. P. M., Reynolds, K. L., Rahma, O. E., Lorigan, P. C., Carvajal, R. D., Lo, S., Mandala, M., & Long, G. V. (2021). clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. Journal for immunotherapy of cancer, 9(1), . http://access.bl.uk/ark:/81055/vdc_100127572643.0x000032